Drug delivery using ADEPT antibody is under quick development and this approach has been tested in the clinic as a treatment for advanced colorectal carcinoma. One advantage of ADEPT is that small cytotoxic agents produced within a tumor site by the enzyme-mediated prodrug conversion has better tumor penetration than a large antibody molecule. https://www.creative-biolabs.com/adc/toxic-enzymes-adept.htm
Cancer Research